New York City
Monday, May 27, 2024
“THE CEO PUBLICATION owns both theceopublication.com and theceopublications.com websites"

Publication

Moderna CEO expects Covid variants to emerge in coming months: 'This virus is not going away

Moderna CEO expects Covid variants to emerge in coming months

May 10, 2021: – Moderna CEO Stephane Bancel said the company expects the Covid-19 variants will emerge in the future months as the Southern Hemisphere will come its fall and winter seasons.

Bancel said to investors on an earnings call of the first quarter, said people would probably need to get booster doses of its two-dose Covid-19 vaccine as the virus circulates globally.

“New variants of concern keep emerging worldwide. And it is believed that over the next coming months, as the Southern Hemisphere enters the fall and winter, we could see more variants of concern emerge,” Bancel said.

The Southern Hemisphere includes Africa, Australia, most of South America, and parts of Asia. “We believe booster shots will be needed as we believe the virus is not going away.”

The CEO’s comments come a day after the company announced a booster shot of its vaccine generated a favorable immune response against the B.1.351 and P.1 variants first identified in South Africa and Brazil, respectively. The variants have since spread to other countries, which includes the U.S.

Moderna’s vaccine requires two doses given four weeks apart. Like Pfizer’s and Johnson & Johnson’s, the shot is highly effective against Covid, though company executives and officials now say they expect solid protection for wane over time. Pfizer’s vaccine is also a two-dose regimen, while the J&J immunization is just one jab.

Earlier Thursday, Moderna said sales of its successful vaccine helped drive its first quarterly profit ever.

Moderna’s Covid-19 vaccine generated $1.7 billion in sales, according to its earnings report. The company also raised its 2021 sales forecast for its vaccine to $19.2 billion, up from its previous forecast of $18.4 billion. Bancel said the company is “actively engaged” in discussions and agreements for 2022 with all of the governments it is currently supplying.

Earlier this week, rival Pfizer also raised its vaccine sale forecast, predicting full-year sales of $26 billion.

Get The Latest Updates

Subscribe To Our Weekly Newsletter

No spam, notifications only about new products, updates.

Most Popular

Receive the latest news

Request for online magazine

Join Us

Advertise with us

meteroid vecrtor
Receive the latest news

Contact Us